Trial | NCT04457037  Report issue

Title

Treatment of Patients With Trophic Ulcers Using Mesenchymal Stem Cells
Treatment of Patients With Trophic Ulcers Using Autologous Adipose-derived Mesenchymal Stem Cells

  • Phase

    Phase 1/Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    18
Treatment of patients with trophic ulcers using injection of autologous adipose-derived mesenchymal stem cells around and inside the wound
During the implementation of the project, it was planned to develop a method for the treatment of trophic ulcers using injection of autologous adipose-derived mesenchymal stem cells in the wound. The positive outlook for the effectiveness of MSCs is due to the following:

the ability of MSCs to stimulate tissue regeneration
positive results of preclinical studies of the method of treatment of trophic ulcers in animals (rats).

In study were included 18 patients (28 trophic ulcers treated). MSCs will be isolated from adipose tissue, cultured and then transplanted back to the wound. From 1 to 10 million MSCs in 4 ml were injected depending on the area of the wound. Follow up patients monitoring will occur at 1，2 and 3, 6, 12, 22 months after injection.
Study Started
Oct 01
2009
Primary Completion
Dec 31
2013
Study Completion
Dec 31
2013
Last Update
Jul 07
2020

Biological Autologous adipose-derived mesenchymal stem cells

Autologous adipose-derived mesenchymal stem cells

MSC Experimental

Patients with trophic ulcers received standard treatment and MSC

Criteria 

Inclusion Criteria:

Trophic Ulcers

Exclusion Criteria:

diagnosed cancer
acute and chronic infectious diseases: HIV, viral hepatitis, tuberculosis
mental disorders
pregnancy
No Results Posted